Modulation of S1P in the Treatment of Autoimmune Diseases
We recommend
VIDEO: Ozanimod v terapii relabující-remitující roztroušené sklerózy
Od března letošního roku je v Česku hrazen modulátor receptoru pro sfingosin-1-fosfát (S1PR) ozanimod pro léčbu pacientů s aktivní relabující-remitující roztroušenou sklerózou (RRRS). V této souvislosti se 31. května 2023 v Brně uskutečnilo sympozium diskutující význam nově dostupné modality a jejího místa v terapii RRRS. MUDr. Pavel Hradílek, Ph.D., z Neurologické kliniky LF UO a FN Ostrava se věnoval problematice ztráty mozkové hmoty a její důležitosti jakožto parametru RS. Přednosta Ústavu farmakologie LF UP a FN Olomouc doc. MUDr.…
Co je možné očekávat od ozanimodu v indikaci UC?
Na sympoziu „Zeposia Stand Alone Meeting“ společnosti Bristol Myers Squibb bylo představeno nové…
Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It…
Articles on this topic
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based…
Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
The sphingosine-1-phosphate receptor (S1PR) modulator ozanimod has recently been approved for…
Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
As a review article published last year in the journal Drugs suggests, ozanimod is an…
Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for…
Invitation to ZEPOSIA STAND ALONE MEETING
On behalf of Bristol Myers Squibb, we warmly invite you to the Zeposia Stand Alone Meeting, which...
Subscribe
Conferences news
Go to records
Go to records
Most read on this topic
- Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
- Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
- Invitation to ZEPOSIA STAND ALONE MEETING
- Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
- Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
- Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Journal on this topic
Related topic
Interesting links